- 1 Evaluation of a One Health public health program based on minimum inputs to control Taenia
- 2 *solium* in Madagascar
- 3 Diana Edithe Andria-Mananjara^{1*}, Modestine Raliniaina¹, Mihaja Rakotoarinoro¹, José A Nely²,
- 4 Nivohanitra Razafindraibe^{3,4}, Sylvia Noromanana Ramiandrasoa⁵, Betthelhein Ramahefasoa³,
- 5 Valisoa Claude Rakotoarison¹, Paul R. Torgerson⁶, Eric Cardinale^{7,8}, Harena Rasamoelina-
- 6 Andriamanivo⁴, Glenn Edosoa⁹, Agnès Fleury^{10,11}, Kabemba E. Mwape¹², Bernadette Abela¹³,
- 7 Marshall W. Lightowlers¹⁴, Meritxell Donadeu^{14,15*}
- 8
- 9 ¹National Center for Applied Research on Rural Development (FOFIFA), BP04 Rue Farafaty
- 10 Ampandrianomby, Antananarivo, Madagascar
- 11 ²Ministry of Health of Madagascar, Building CHU-SSPA, ex-HIS Analakely, Tananarive,
- 12 Madagascar
- 13 ³Directorate of Veterinary Services, Ministry of Agriculture and Livestock, Ampandrianomby,
- 14 Madagascar
- 15 ⁴CDC-One Health Indian Ocean-Indian Ocean Commission/SEGA-One Health Network
- 16 ⁵Consultant, Lot ITP22, Andrambato Itaosy, Antananarivo 102, Madagascar
- ¹⁷ ⁶Section of Epidemiology, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland
- 18 ⁷CIRAD, Montpellier, France
- 19⁸University of La Réunion
- ⁹WHO Country Office, United Nations Common Building, Galaxy Area, Andraharo, BP 362,
- 21 Antananarivo 101, Madagascar
- ¹⁰ Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones
- 23 Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México, México
- ¹¹ Clínica de neurocisticercosis, Instituto Nacional de Neurología y Neurocirugía, Ciudad de
 México, México
- ¹²Department of Clinical Studies, School of Veterinary Medicine, University of Zambia, Lusaka,
 Zambia
- ¹³Department of the Control of Neglected Tropical Diseases, World Health Organization,
 Geneva, Switzerland
- ¹⁴Department of Biosciences, Melbourne Veterinary School, University of Melbourne, 250
- 31 Princes Highway, Werribee, Victoria, Australia
- 32 ¹⁵Initiative for Neglected Animal Diseases (INAND), Midrand, South Africa
- 33 Corresponding authors:
- 34 *dianaandria21@gmail.com (DEAM); Meritxell.Donadeu@gmail.com (MD)

35 Abstract

36 Cysticercosis in humans caused by the parasite *Taenia solium* is one of the World Health

- 37 Organization's Neglected Tropical Diseases. The parasite is transmitted between the human host
- and pigs. Efforts to prevent the disease have relied mainly on treatment of people with
- 39 anthelmintics. However to date there is no practical and effective control method that has been
- 40 delivered as a public health program. Here we describe a large-scale, minimum inputs *T. solium*
- 41 control program implemented as a public health program in Madagascar. Initially pigs were
- 42 vaccinated for porcine cysticercosis and medicated with oxfendazole, after which only young
- 43 piglets and pigs imported into the program area were targeted for interventions. After piglet
- 44 interventions were in place and on-going, a single mass drug administration (MDA) was
- delivered to the human population with a taeniacide. The outcomes were assessed one year after
- the human treatment, by comparing pre-and post-intervention levels of human *T. solium* taeniasis
- 47 and porcine cysticercosis caused by *T. solium*. Over a twenty-two-month period, 96,735 pig
- vaccinations were delivered and during the MDA, 117,216 people received taeniacide. Ninety
- 49 percent of the pig population were receiving vaccination and medication at the end of the
- 50 intervention period. Coverage of the eligible human population by the MDA was 62.5%. Human
- taeniasis was found to be 1.25% prior to the MDA and 0.6% one year after the MDA. Prior to the
- 52 intervention 30.8% of slaughter-age pigs had viable *T. solium* infection whereas no viable
- 53 infection was detected in any pig treated in the program. The program successfully demonstrated
- 54 effective control of *T. solium* transmission using minimum inputs and delivered as a public health
- 55 program. Sustained control and expansion of the program could potentially lead to the
- se elimination of the disease being a public health problem in Madagascar.
- 57

58 Author summary

Cysticercosis caused by the cestode parasite *Taenia solium* is one of the World Health 59 Organization's neglected tropical diseases. We implemented One Health cysticercosis control as a 60 public health program in a highly endemic region of Madagascar. The program was designed to 61 require minimum inputs while achieving maximum impacts on control within a short period of 62 time. Pigs were vaccinated with the TSOL18 vaccine and simultaneously treated with oxfendazole. 63 Over a 2-year period, piglets 2-3 months of age were treated. After pig vaccination practices where 64 established, the human population received a single treatment with a taeniacide. The program was 65 evaluated by assessment of porcine cysticercosis and human taeniasis before and 12 months after 66 the human mass drug administration. More than 95,000 pig vaccinations were delivered and 67 117,000 persons received taeniacide. The intervention entirely eliminated viable porcine 68 cysticercosis in slaughter-age pigs that had received treatment as well as reducing human taeniasis. 69 70 Continuation and expansion of the program would have the potential to eliminate T. solium from the program area, or even from the entire country. 71

73 Introduction

- 74 Neurocysticercosis (NCC) is an infection of the central nervous system caused by the larval stage
- of a zoonotic parasite, *Taenia solium* [1]. It is prevalent in many parts of the world where risk
- ⁷⁶ factors for the parasite's life cycle are present, such as poverty, lack of hygiene and sanitation,
- and the presence of free-roaming pigs [1]. As a result, many low and middle income countries,
- including Madagascar, are endemic to *T. solium* [2, 3], and NCC is a leading cause of epilepsy in
- the population [4].
- 80 NCC is considered a preventable and potentially eradicable neglected tropical disease [5]. So far,
- attempts to control transmission of *T. solium* have relied mainly on preventive chemotherapy in
- humans using either praziquantel or niclosamide [6-9]. Another tool available for the control of
- 83 *T. solium* is the combined use of the TSOL18 (Cysvax®) porcine cysticercosis vaccine together
- 84 with a single treatment with oxfendazole in pigs. The vaccine has proved to be safe and efficient,
- and the combination with oxfendazole has been found to eliminate parasite transmission by the
- treated pigs in field trials undertaken in Nepal, Cameroon and Uganda [10-12].
- 87 One Health research projects based on mass drug administration (MDA) and/or targeted
- chemotherapy in combination with other One Health measures (mainly pig vaccination and/or
- 89 treatment) have achieved a reduction in *T. solium* transmission [13-17]. However, the approaches
- 90 used have been neither practical, sustainable nor able to be implemented successfully as public
- 91 health programs. There are currently no validated models for the control of the parasite.
- 92 Here we sought to evaluate the effectiveness of a *T. solium* control strategy requiring minimum
- 93 inputs with the potential to lead to a substantial and sustainable reduction in parasite
- 94 transmission, and delivered as a public health program by the Veterinary Services of the Ministry
- of Livestock and the Ministry of Public Health of Madagascar. Principal components of the
- program involved vaccination and treatment of young piglets, and a single round of MDA in the
- human population after pig vaccination had been well established. Outcomes were assessed by
- 98 comparing pre and post intervention levels of human *T. solium* taeniasis and porcine
- 99 cysticercosis.

100 Methods


101 Ethics statement

- 102 Intervention and assessment protocols were designed and implemented in compliance with
- 103 ethical approvals for the study granted by the Madagascar Ministry for Public Health Ethics
- 104 Committee for Biomedical Research No. 088-MSANP/SG/AMM/CERBM and by the Malagasy
- 105 National Animal Ethics Committee, No. 001-21/CENA.

106 Study area and timeline

- 107 The control program was implemented from August 2021 to August 2023 in a single contiguous
- 108 area in central Madagascar comprising nine municipalities in two districts of Vakinankaratra
- region, Betafo and Mandoto (Fig 1). The area comprises approximately 420 villages (hamlets)
- spread over 84 fokontany (the lowest administrative unit), 205,197 inhabitants in 45,539

- households [18] and an estimated 27,000 pigs. The most important economic activity among 93%
- of the population is mixed cropping with livestock farming [18]. Pig farming is one the major
- 113 livestock activities of households. It is used as a means of livelihood and a source of savings for
- small scale farmers [19]. The program area was selected because the prevalence of human
- 115 cysticercosis in the region was relatively high [20]. It is also one of the main suppliers of pigs for
- 116 Antsirabe (the largest city in the region) and the capital of Madagascar, Antananarivo [21], and
- 117 cases of porcine cysticercosis were seen frequently in Vakinankaratra compared to other regions
- 118 of the central highlands [22].



119

Fig 1. Taenia solium One Health control program implementation areas in Madagascar

120 **Program design and rationale**

- 121 Interventions to interrupt *T. solium* transmission were undertaken in the two obligate hosts of the
- 122 parasite, pigs and humans. Implementations were designed as One Health interdependent actions
- 123 and included training of actors, advocacy and social mobilization to maximize the involvement of
- the relevant stakeholders.
- 125 The timings of the interventions were a key component of the program design. Because humans
- 126 after receiving the MDA can get infected or re-infected with *T. solium* after ingesting
- 127 contaminated pork (as there is no immunity to the tapeworm), the first step was to reduce the risk
- 128 of infection in humans by reducing the prevalence of the disease in the pig population. Therefore,
- 129 the first step was to vaccinate and treat the pigs to minimise the risk of infection or reinfection in
- 130 humans. Only when that risk was minimised by having the pig population vaccinated and
- 131 treated, then the MDA was to be conducted. However, because of the likely imperfect coverage
- 132 of the MDA, and the potential risk of tapeworm eggs surviving in the environment, the
- 133 vaccination of piglets and incoming pigs continued for a year after the MDA.
- 134 While the implementation was based on activities conducted as a public health program
- 135 (therefore implemented by existing staff linked to the Ministry of Public Health or the Veterinary

136 Services), the evaluation was conducted as a research project so as to obtain accurate measures of

the impact of the intervention on *T. solium* transmission. The local coordination and supervision

138 were provided by the National Center for Applied Research on Rural Development (FOFIFA).

139 **Pig intervention**

140 Intervention activities in pigs were undertaken between October 2021 and August 2023. Initially

141 a census of the pig population in the program areas was conducted to determine the number of

142 pigs. Subsequently, pigs in the area were vaccinated with the TSOL18 vaccine (Cysvax® from

143 Indian Immunologicals Limited) and, simultaneously, received an oral treatment with

144 oxfendazole (Oxfenvet® from Indian Immunologicals Limited). Interventions in the pig

145 population were undertaken by the staff of the Ministry of Livestock through the Veterinary

146 Services Directorate, the sanitary veterinarians and their animal health agents (vaccinators).

At the start of the program, the intervention targeted all the pigs in the population. Inclusion 147 criteria were animals ≥ 2 months of age, showing no obvious signs of sickness and not pregnant 148 or lactating. The animals received two immunizations, approximately one month apart, with the 149 Cysvax® vaccine and, at the time of the second immunization they also received treatment with 150 oxfendazole at 30 mg/kg. Subsequently, throughout the program, newborn piglets (at \geq 2 months 151 of age) and any pigs imported into the program area received both Cysvax vaccination and 152 oxfendazole treatment twice, at least 1 month apart (Fig 2). At the time of the first vaccination 153 and treatment, the animals were tagged with a button tag in one ear. At the time of the second 154 vaccination and treatment, the button tag was marked with indelible pen. Vaccinators visited the 155 villages approximately on a monthly basis, and farmers having newborn piglets or imported 156 animals were identified by the farmer themselves, the Chief of the fokontany or neighbouring 157 farmers. The program aimed to identify and treat any animals which did not initially receive 158 treatment for some reason during the following monthly visits to the farms. The interval between 159 vaccinations is not critical and intervals of 2-4 months between primary and secondary 160 immunization provide as good, or better, response to the vaccine [23]. The strategy was efficient 161 in targeting piglets but less reliably for older animals as they were often roaming in the fields and 162

163 difficult to reach.

Pig vaccination and treatment coverage was not measured precisely, as it would have required 164 greater resources and logistics than were available. From August 2022, it was decided to use a 165 proxy measure, by asking the vaccinators to record the vaccination status of the pigs they meet 166 during their monthly vaccinations. Because the vaccinators were only going to the households 167 where they knew there were pigs to be vaccinated (as learned from previous visits, the Chief of 168 the fokontany or other farms), they were not capturing the total population as they were not going 169 to households where, for example, all the pigs were already vaccinated. This is an imperfect 170 measure as pigs could have been missed, but it helped to identify areas where the coverage was 171 'lower' and where additional awareness efforts were required. 172

173 Vaccinators were required to maintain strict biosecurity measures to prevent the spread of pig

diseases, in particular African and Classical swine fevers. Disinfection of boots, overalls, lassoes,

and other equipment with Virokil® was mandatory before entering and after leaving a farm.

176 Vaccine and oxfendazole were administered using single use disposable syringes. Any waste was

177 stored in special bags and transported to the veterinarians, who in turn disposed of it in an

178 appropriate manner.

179 Human intervention

A single MDA was undertaken in the human population once the intervention in the pig 180 181 population was fully established (August 2022, Fig 2). The MDA was initially planned for December 2021, but due to adverse events with a child receiving praziguantel during a MDA 182 program for schistosomiasis in a nearby district, the Ministry of Public Health delayed all the 183 MDA interventions until further training and preventive measures were put in place. For that 184 reason, the MDA was not undertaken until August 2022. The Ministry of Public Health through 185 its communicable disease control department and the local medical staff (regional and district 186 responsible for neglected tropical diseases, chiefs of health centers and community health 187 188 agents), undertook the MDA campaign in all the eligible population over 5 years of age. The main drug used was praziguantel (Cesol[™] from Merck or Biltricide® from Bayer). As MDA 189 with praziquantel was already part of the Ministry of Public Health's annual program for 190 treatment of schistosomiasis (co-endemic with Taenia solium in this region), the MDA was 191 conducted by the Ministry of Public Health in synergy with their MDA campaign against 192 schistosomiasis. Children between 5 and 15 years of age targeted by the schistosomiasis program, 193 received praziguantel at 40mg/kg. Additionally, the children in Betafo district, also received 194 195 mebendazole (500mg, Vermox[®] from Johnson & Johnson) as part of the Ministry of Public Health program to control soil-transmitted helminths. People 15 years old and over, were treated 196 with praziguantel at 10mg/kg as a taeniacide. Prior to the MDA, a series of training and activities 197 were undertaken to prevent and minimise neurological adverse events (Nely et al. submitted). 198 Eligibility criteria for praziquantel treatment in people over 5 years of age were: non pregnant 199 women, women who had been breastfeeding for more than 3 months, and people without 200 symptoms or signs compatible with NCC such as seizures and epilepsy or chronic headache. 201 Those exhibiting symptoms or signs compatible with NCC were treated with niclosamide 202 (Yomesan®, Bayer) at a dose of 1g for children from 5 to 6 years of age, and 2g for children over 203 6 years and adults. 204


Active and passive surveillance were conducted to monitor and quickly identify and manage any
 possible adverse events in people who had participated in the MDA (Nely et al. submitted). Local

staff were trained and appropriate medicines were made available at health centers to deal with

side effects, such as neurological events, drug allergies, etc.

209

Fig 2. One Health model for the control of *Taenia solium* in Madagascar. Fig 2A shows the original design, and Fig 2B shows the actual implementation after the MDA had to be delayed.



V+1: Vaccination and treatment MDA: Mass drug administration

210 Training, monitoring and auditing

211 Prior to the interventions, training was undertaken for those involved in activities related to

- 212 animals or humans.
- 213 Veterinarians and vaccinators were trained in vaccination procedures, maintenance of cold chain,
- 214 identification of vaccinated animals, oral drug treatment, coverage data collection, and
- 215 biosecurity measures. Messages and attitudes to transmit to farmers who may have been initially
- reluctant to take part of the campaign were also covered during the training. During the
- vaccination campaign, vaccinators were supervised and audited by local veterinarians as well asby FOFIFA staff.
- 219 Those involved in the human intervention received cascade training. Modules covered a refresher
- 220 on the disease complex, standard operating procedures for the MDA (which is already part of the
- annual Ministry program), key messages to increase participation, coverage data collection,
- active surveillance of NCC cases and potential adverse reactions, and management of adverse
- events (Nely et al., submitted). Monitoring and supervision of activities were undertaken by the
- 224 program's senior staff pre and post-MDA campaign.

225 Community sensitization

- 226 Social mobilization was a key component for this program. The local authorities were the first
- 227 ones to be involved, and with their cooperation awareness campaigns were undertaken to
- 228 facilitate access to beneficiaries and maximize their participation either in the animal or human
- 229 interventions. Traditional singers were recruited to compose awareness-raising songs related to
- the fight against *T. solium* and to perform the songs in local tours in the municipalities covered by
- the program. In addition, radio spots were strategically broadcasted on local channels. The key

- 232 messages for these two types of sensitizations were related to the parasite's transmission, the
- 233 importance of the fight against *T. solium*, encouragement of farmers to participate in the pig
- vaccination, encouragement of people to participate in the MDA, and the clarification of any
- 235 negative rumours circulating about the interventions.
- 236 Posters were produced in local language and posted in the villages or used at community
- 237 meetings. The program used the WHO/WOAH/FAO T. solium poster on the cycle of the parasite
- and the possible ways of control [24]. Other posters on the identification and management of
- adverse events were also prepared and used during the MDA (Nely et al, submitted).

240 Data collection

- 241 Data from all interventions were recorded through paper-based forms. For pig interventions, data
- 242 was recorded monthly by vaccinators and focused on the number of animals in each farm, the
- 243 number of vaccinated animals according to the number of immunizations provided, and the
- number of non-vaccinated animals per category (< 2 months, pregnant sow, lactating sow). Local
- supervising veterinarians collected all data recorded and made a monthly report for the seniorstaff.
- For the MDA, data collected related to the demographic characteristic of the person who received
- 248 the drug, the presence of signs compatible with NCC, the drug administered, adverse events, the
- 249 clinical signs linked to the adverse event, and the treatment received.

250 **Program evaluation**

- 251 The program was evaluated by determining changes in the prevalence of porcine cysticercosis
- and the prevalence of human *T. solium* taeniasis. The objective was always to conduct the endline
- evaluation one year after the MDA, so because the MDA was delayed, the final evaluation was
- also delayed. Baseline and endline evaluations were conducted, respectively, in August 2021 and
- August 2023 for porcine cysticercosis. Evaluations for *T. solium* taeniasis were carried in October
- 256 2021 (repeated in December 2021) and August 2023.
- 257 Porcine cysticercosis was determined by detailed necropsy examination on 104 slaughter-age
- pigs selected randomly and purchased from the population. The same 26 fokontany randomly
- selected for sampling at baseline were also sampled at endline evaluation. The sample size for
- 260 necropsy assessment (104 animals) was calculated from a population of 45,000 pigs (as per the
- latest official census) distributed in 20 villages, each ranging from 350 animals upwards per
- village, with the samples assumed to be aggregated. The expected initial necropsy prevalence was
- 263 15%. Samples size was calculated with a power of 90% and 99% confidence interval.
- 264 Calculations were done in R (version 3.6.0) via Monte-Carlo simulations. Necropsies were
- undertaken as previously described [25]. Briefly, the animals were brought to a central veterinary
- facility in Antananarivo where local butchers prepared the carcasses. The muscles of the right-
- hand side of the carcase as well as the masseters, tongue, full diaphragm and heart were dissected
- from the bodies and sliced by hand at approximately 3mm intervals to reveal all cysts. Where no
- 269 cysts were identified, the left-hand side of the carcase was assessed for possible infection in a
- similar way. Cysts were recorded as either viable or non-viable and their numbers were counted
 to determine the level of infection. For the endline assessments, 104 animals were randomly

selected (independently of their vaccination and treatment status), and an additional 16 slaughter-

- age pigs were selected at random from those in the population that had not received any
- vaccination or oxfendazole, to have a total of 50 non vaccinated or treated pigs.

The prevalence of human T. solium taeniasis was determined by Kato-Katz thick smear as 275 described in the World Health Organization (WHO) Bench aid for the diagnosis of intestinal 276 procedures [26]. The first evaluation conducted in October 2021 only found four positive 277 278 samples, which was not congruent with the high level of infection in pigs determined during the baseline necropsies. Therefore, the sampling design was adjusted, and a new purposive sampling 279 was conducted, targeting only villages in which roaming pigs and deficient sanitation were 280 present, but randomly selecting the people within those villages. The number of samples per 281 village was also proportional to the number of pigs in the village, and not to the number of 282 people, as due to the cycle of the parasite, it is less likely that there is active transmission in the 283 larger towns in which there are fewer (or no) roaming pigs and better sanitation. In summary, for 284 the new baseline and the final evaluation, faecal samples from 960 people were purposively 285 sampled (according to the size of the pig population) from throughout 26 fokontany. For the 286 baseline evaluation, one smear was prepared for most of the samples, while 2 smears were 287 examined for 78 samples. Confirmation of the Taenia species present in Kato-Katz positive 288 samples was performed by PCR and sequencing of a segment of the small subunit of 289 mitochondrial ribosomal RNA (rrnS) gene, as described in Lightowlers et al. [27]. All endline 290 examinations were undertaken on duplicate smears. Sample size was calculated from an 291

- estimated target population of 190,000 which would detect a reduction in prevalence from 1.8%
- 293 to <0.1%, with a power of 90% and confidence level of 99%. Calculations were done in R via
- 294 Monte-Carlo simulations.

295 Data Analysis

- All collected data were entered into Microsoft Office Excel ® spreadsheets. Statistical analyses
 were performed using R 4.3.0 software.
- 298 The coverage rate for pig interventions were calculated based on the number of pigs that received
- one dose or two doses of Cysvax and the total number of eligible pigs in the area. Pigs that were
- 300 considered not to pose a risk for *T. solium* transmission were those that were less than 2 months
- 301 of age, those that had received one treatment (vaccine and oxfendazole) within the previous 2
- 302 months and those that had received two treatments (vaccine and oxfendazole).
- 303 Levels of porcine cysticercosis in slaughter-age pigs in the intervention area before the
- intervention and in non-vaccinated or treated animals at the time of the final evaluation were
- 305 compared using a negative binomial general linear model.
- 306 For human interventions, the coverage was calculated based on the number of people who
- 307 received treatment during the MDA and the number of eligible targeted population. Categorical
- 308 outcomes, which are the prevalences of porcine cysticercosis with viable cysts and human
- 309 taeniasis before and after the interventions were compared between study groups using Chi
- square test /Fisher's Exact test. A p value <0.05 was considered statistically significant.

311 **Results**

312 3.1 Initial pig census

The number of pigs in the intervention area was assessed to be 27,071 belonging to 12,006 pig

farmers, representing an estimated average of 2 pigs per farm. The majority of farmers allowed

their pigs to roam freely. Some pigs went with the farmers to the field during their agricultural


activities, while others roam around the villages to search for food. Most of the time, breeding

317 pigs and their piglets, as well as pigs entering the fattening phase, are left free to roam, and some


318 will only be confined in a pigsty at the end of the fattening phase.

319 3.2 Pig treatment and vaccination

- 320 The initial vaccination and treatment of the pig population (from October to November 2021)
- reached 19,135 pigs for the first immunization, representing 70.68% of the pig population
- 322 determined by the census prior to the beginning of vaccinations. For the second immunizations
- the number of pigs vaccinated decreased to 8,120 of those previously vaccinated (p<0.001 95%
- 324 CI 0.32 0.52). This change was associated with the appearance or unsubstantiated and often
- 325 outrageous rumours. Efforts were made subsequently to identify and vaccinate those pigs that
- 326 missed the second scheduled immunization during the following visits, however as these animals
- 327 were typically in the fields and hence unavailable when the vaccinators visited the farms.
- 328 Vaccinations that subsequently targeted piglets > 2 months and new imported pigs increased
- progressively in number throughout the intervention period (Fig 3). On average, 3,309 (SD \pm
- 330 1,434) vaccinations per month were carried out. The number of vaccinations per month increased
- fourfold between January 2022 and August 2023. In total, 96,735 vaccinations were delivered
- 332 during the program.



333



- Data on the coverage rate of vaccination and treatments was obtained from vaccinators from 334
- August 2022 onwards and also from the random selection of pigs used for the endline evaluation 335 necropsies. 336
- On average, vaccinators identified approximately 7,000 pigs (eligible and ineligible, vaccinated 337
- and unvaccinated) per month. The coverage per month and the proportion of the total pig 338
- population that were considered to pose no risk for transmission of T. solium varied from one 339
- fokontany to another. Detailed records of vaccination coverage show a progressive increase in the 340
- percentage of the 84 fokontany achieving a coverage over 75% with >92% coverage achieved in 341
- the final months of the program (Fig 4). 342
- From August 2022 when proxy detailed coverage was obtained until the end of the year (5 343
- months), 11 fokontany out of the 84 had a coverage <50% (seven fokontany on one occasion, 344
- three fokontany on two occasions, and one fokontany on 3 occasions). In comparison, during the 345
- 8 months of 2023, only one fokontany had once a coverage below 50%. 346
 - 100% 90% 80% 70% 60% 50% 40% Jan 23 Marilas P61-23 AUGT22 Sepili OCtill 404.22 Decill 400-23 May23 Jun-23 JU1-23 AUGS23



- achieved a coverage \geq 75% of the pig population for vaccination and treatment as recorded by the 349 pig vaccinators. 350
- 351

347

- The data for vaccination coverage from the random selection of pigs during the endline 352
- evaluation was 67.30%, which indicated that among 104 randomly selected pigs, 70 pigs were 353
- vaccinated and 34 of pigs were not vaccinated. 354
- 3.3 Human intervention 355

- In total, 117,216 persons were treated during the MDA, which represented 62.52% of the eligible
- population (187,490 out of 231,755 total population). Significant differences in treatment
- 358 coverage rates were observed between municipalities (Table 1). Fidirana municipality had the
- 359 highest number of people treated, with a coverage rate approaching 90%, while Soavina
- 360 represented the area with the lowest participation, with 40% of the population. There was no
- 361 significant difference observed between the proportion of children under 15 treated and the
- proportion of people over 15 years of age that participated in the MDA (p>0.05). Among the
- 363 persons treated, 615 received niclosamide as they were identified as having symptoms or signs
- 364 compatible with NCC, which represent 0.52% of the treated population. Among persons treated
- with niclosamide, the number of people more than 15 years old was higher than the number of
- 366 children less than 15 years old (p < 0,0001).

Table 1. Population treatment data for the taeniacide MDA intervention

Municipalities areas	Total Populati on	Children 5 to 14 years old	People > 15 years old	Children 5 to 14 years old treated (%)		People > 15 years old treated (%)		MDA coverage (%)
				Praziquantel	Niclosamide	Praziquantel	Niclosamide	
Ambohimasina	26,727	7,350	14,272	4,443 (40.48)	6 (0.05)	6,489 (59.13)	37 (0.34)	10,975(50.76) ^a
Inanantonana	17,012	4,678	9,084	3,357 (33.44)	0	6,681 (66.56)	0	10,038 (72.94) ^b
Ambohimanambola	31,037	8,535	16,574	5,633 (37.12)	7 (0.05)	9,423 (62.09)	113 (0.74)	15,176 (60.44)°
Soavina	19,046	5,238	10,171	2,723 (43.92)	1 (0.02)	3,458 (55.77)	18 (0.29)	6,200 (40.24) ^d
Antohobe	17,877	4,917	9,546	3,217 (39.93)	15 (0.19)	4,790 (59.46)	34 (0.42)	8,056 (55.70) ^e
Ankazomiriotra	41,800	11,495	22,322	6,440 (36.17)	34 (0.19)	11,217 (63.00)	113 (0.63)	17,804 (52.65) ^f
Betsohana	12,188	3,352	6,508	2,779 (32.06)	17 (0.20)	5,823 (67.18)	49 (0.57)	8,668 (87.91) ^g
Fidirana	38,308	10,534	20,456	9,641 (34.65)	20 (0.07)	18,101 (65.05)	65 (0.23)	27,827 (89.79) ^h
Vinany	27,760	7,634	14,824	4,205 (33.72)	10 (0.08)	8,181 (65.59)	76 (0.61)	12,472 (55.53) ⁱ
TOTAL	231,755	63,733	123,757	42,438 (36.20)	110 (0.09) ^j	74,163 (63.27)	505 (0.43) ^k	117,216 (62.52)
				42,548 (66.76)		77,668 (60.33)		

368 a,b,c,d,e,f,g,h,i : p<0,0001; j vs k: p<0,0001; No significant difference between the proportion of children <15 years old treated and People >=15 years old treated

367

- 369 There was one case of a severe neurological adverse event. A 13-year-old child among those
- treated with praziquantel, presented in the evening of the first day of MDA headache, which
- became stronger during the night; the next day, he vomited and had seizures. This severe adverse
- event was promptly identified and managed as per established protocols (Nely et al submitted). A
- 373 CT scan revealed three parenchymal NCC lesions. The child received appropriate medical care,
- there have been no recurrence of seizures and is leading a normal life.

375 **3.4 Program evaluation - pigs**

- The randomly selected slaughter-age animals assessed at the endline necropsies comprised 70
- vaccinated and treated pigs and 34 untreated pigs (Table 2). Among the vaccinated animals, no
- viable *T. solium* cysts were found. Five treated and vaccinated animals were found to have non-
- viable lesions in the muscles (4 animals with up to 10 lesions, one with 83 lesions). Among the
- slaughter-age pigs that had not been vaccinated and treated, 8 (23.5%) were found to be infected
- with viable *T. solium* cysts. Comparison of the prevalence of viable *T. solium* infection between
- baseline and final showed a significant difference in the prevalence of porcine cysticercosis (x, (0, 0, 0, 1)).
- (p<0.001). Comparison of the entire pig population between baseline and final evaluations showed a statistically significant decrease in viable infections with *T. solium* from 30.77 to
- 385 7.69%.
- 386 Among the total of 50 slaughter-age pigs that were evaluated by necropsy and had not received
- any vaccination or oxfendazole, that is the 34 pigs randomly selected for the final evaluation plus
- the additional 16 randomly selected amongst the non-vaccinated or treated, 15 (30%) were found
- to have *T. solium* cysticerci in their muscles (either viable or non-viable).

Evaluation	Baseline	Endline	
Status of pigs	Non vaccinated	Vaccinated	Non vaccinated
Number of pigs	104	70	34
Number with viable cysts			
1 - 10 cysts	8		6
11 - 100 cysts	8		1
101 - 500 cysts	11		1
>500 cysts	5		0
Number with only non-viable cysts	5	5	1
Number with no cysts	67	65	25

Table 2. Necropsy results of the baseline and endline program evaluations

Prevalence with viable cysts % (95% CI)	30.77° (22.08-	0ª (0-5.13)	23.53 ^b (10.74- 41.17)
	40.57)	7,69 ^d (3.37-14.59)	

390 a vs b ; a vs c ; c vs d p<0,001 c vs b p=0.42

391 3.4 Program evaluation - humans

392 Assessment of 960 people randomly selected from the population, Kato-Katz identified taeniasis

in 12 persons (1.25%) at baseline [27] and 6 persons (0.6%) one year after the single MDA

intervention. The difference was not statistically significant (p=0.13). Of the total 18 positive

fecal samples, 15 (9 from baseline, and 6 from final evaluation) were able to be confirmed to

species level by copro-PCR and DNA sequencing; all were confirmed as *T. solium*.

397 Among the samples tested at baseline, all the egg-positive samples were identified to be positive

among the samples examined in a single Kato Katz slide except for one, which was identified

among the 78 baseline samples tested by 2 slides, and it was positive in both slides. The six

samples identified as Kato-Katz positive during the final evaluations were all positive in both

401 slides tested.

402 **Discussion**

403 The strategy of piglet vaccination and oxfendazole treatment eliminated the potential for T. solium transmission by the pigs that participated in the program. Of 70 treated, slaughter-age animals that 404 405 were examined by slicing the entire striated musculature of the animals, no infection with viable T. solium was identified in any animal. Five animals were identified with non-viable cysts only. 406 407 The *T. solium* vaccine targets an antigen uniquely associated with the oncosphere life cycle stage [28] and is not believed to affect cysticerci that may have established in the tissues prior to 408 vaccination. However, the simultaneous treatment with oxfendazole kills any such pre-existing 409 cysts in the muscles [29, 30]. For this reason, the five animals detected with only non-viable lesions 410 in vaccinated and treated pigs at the endline necropsies are interpreted as being animals that had 411 been exposed to infection prior to treatment [29, 30]. The important point is that these non-viable 412 lesions present no risk of transmission of infection. By comparison, prior to the interventions 30.8% 413 of similarly aged animals had viable *T. solium* infection in their musculature. The finding that some 414 of the piglets were likely to have been exposed to T. solium prior to being vaccinated and treated 415 highlights the importance of delivering the oxfendazole dose in full to the piglets; failure to do so 416 could potentially result in the presence of viable cysts in vaccinated animals (due to infections 417 418 established prior to vaccination) which could appear as vaccine failures.

- 419 A highly significant reduction was observed in the number of *T. solium* cysts (viable or non-viable)
- 420 in non-vaccinated or treated animals that were evaluated at the final evaluation, compared to the
- 421 animals assessed at baseline (Table 3, p = 0.0005). This is interpreted as reflecting a reduction in
- 422 environmental contamination with *T. solium* eggs in the intervention area.
- 423

Table 3. Reduction in environmental contamination with *T. solium* measured as a proxy in nonvaccinated pigs. The number of *T. solium* cysticerci (viable and non-viable) was evaluated by necropsy in non-vaccinated or treated pigs before and after the intervention.

427

	Number of pigs evaluated		Mean number of <i>T</i> . <i>solium</i> cysts in infected animals	
Baseline	104	37	464ª	226-1195
Final evaluation	50	9	26 ^b	10-93

428 ^a vs ^b p=0.00005

429

There was a seasonal variation in the coverage of pig treatments, influenced by other farming 430 activities which resulted in the farmers leaving the house very early and not being available to 431 facilitate the vaccination, or by the farmers taking the pigs with them to the fields, such as during 432 the months of December and January which is the rice transplanting season, or harvesting time in 433 June. Throughout the program the coverage rate of the pig population for treatments steadily 434 435 increased (Fig 4). Soon after the program began, rumours began to circulate that caused many farmers to decline to have their animals vaccinated. For example, it was believed by some that 436 the program was a conspiracy by the government to stop the farmers from breeding local breeds 437 438 of pigs. It also coincided with a high anti-vaccine general attitude in the population due to the ongoing issues concerning human vaccination for COVID. The farmers rarely vaccinated their 439 animals for any purpose even though epidemics of Classical Swine Fever cause mass pig 440 mortality, and hence they have a rudimentary understanding of vaccines, if any. Our use of ear 441 tags to indicated vaccinated animals was initially also a source of concern for the farmers as it 442 was not usual. Continuing efforts throughout the program to educate the farmers and dispel the 443 rumours saw the dissipation of negative rumours and a steadily increasing rate of participation. 444 The fact that treated animals were often judged by farmers to be growing faster helped improve 445 the participation rate. This could be due to the effect of the oxfendazole treatment on nematode 446 and other parasitic infections [31, 32]. 447

The endline assessment in pigs was undertaken in slaughter age animals, more than 8 months of 448 age and generally around 12 months of age (born between September 2022 and January 2023). 449 These animals were raised when coverage of the pig population was 67% (as judged by the 450 randomly selected slaughter-age animals taken for endline necropsy). Hence the 75% decrease in 451 the prevalence of viable *T. solium* infection in the pig population (30.8% to 7.7%) was achieved in 452 animals born between September 2022 and January 2023 when coverage was around 67%. Given 453 that the vaccination and treatment of piglets eliminated T. solium transmission at the time of 454 slaughter-age in all 70 animals that were assessed and had participated in the program, it could be 455 expected that the program would have achieved a 90% reduction in transmission through pigs had 456 it been possible to undertake necropsies at slaughter-age for animals born later in the program when 457 the piglet coverage rate had increased to 90%. A program of continued piglet vaccination and 458

treatment and similar intervention of animals imported into the program area, would maintain
control of *T. solium* transmission indefinitely. In Madagascar it may be possible to eliminate
transmission by extending the program to the entire country.

The intervention program met a major challenge with implementing the planned MDA in 462 humans. The plan was to undertake the MDA a short time after the entire pig population had been 463 vaccinated and treated, and piglet vaccinations were well established and continuing. However, a 464 serious adverse event in 2021 during the routine Malagasy schistosomiasis MDA program with 465 praziguantel resulted in a child's death in a district nearby the program area, delaying the MDA of 466 this program until further measures were put in place. This situation also had an impact on the 467 population's participation in the program's MDA. The population coverage for the MDA was 468 62.5% while the objective was to reach >75% of the population. This being the case, it was not 469 surprising to find that T. solium taeniasis remained present in the population at the endline 470 assessments and transmission continued to non-treated pigs (as evidenced by the rate of infection 471 472 in the 50 non vaccinated pigs). An earlier taeniasis MDA program in Madagascar, in a nearby area undertaken prior to the occurrence of the aforementioned adverse event achieved a 95% 473 coverage [9], suggesting that the population is not averse to participating in MDA programs. Had 474

there been more time between the adverse event that occurred during the schistosomiasis program

and our MDA, a higher coverage of the population is likely to have been achieved.

477 An unanticipated but valuable outcome of our program has been the development of protocols,

478 resources and a strategy to minimize the potential for adverse events occurring due to MDA

479 being undertaken with praziquantel in an area that is, or may be, endemic for *T. solium*. These

resources are available through the WHO [33, 34] and the measures are discussed in full by Nely

481 et al. (submitted).

482 A feature of this *T. solium* control program was that it was implemented not as a research project,

but as a public health program, carried out by the two responsible ministries in Madagascar

484 (Ministry of Public Health and Ministry of Livestock). In this way, it was implemented by

existing and already responsible structures. It was provided to all the people in the control region,

486 without cost. The involvement of the Ministries was planned with a view to appropriation and

sustainability, as well as extension once the program was completed and demonstrated to be

488 successful. Although the program was implemented as a public health program, it was evaluated

as if it had been a research project so as to obtain an accurate evaluation of its impacts.

490 An additional outcome of the program, was an improved relationship between the Ministries and

491 other relevant stakeholders, reflecting the benefits of strengthening the One Health systems for

492 future collaborations and preparedness for future challenges.

493 The program was designed to require minimum inputs and to have a rapid impact, so as to

494 maximize the feasibility of the program being implemented in other *T. solium* endemic regions of

495 Madagascar, and elsewhere. With minimum inputs we refer to only one MDA and one

intervention in the whole pig population, followed only by intervention in piglets and incoming

497 new pigs. The fact that the whole pig population is only dealt with at the start at the program, and

498 from then onwards only piglets and new incoming pigs were treated, facilitated the field work, as

499 having to catch large roaming pigs is not an easy task. The program provided MDA treatment

- 500 drugs through a donation via the WHO and the program funding supported the cost of the
- 501 vaccine, oxfendazole and vaccinators who delivered to program to the animals. Without these
- resources from external donors it is unlikely that control of this neglected zoonosis could be
- 503 undertaken in Madagascar, or elsewhere, where full transmission of the parasite occurs.
- 504 The public health program implemented here achieved the complete cessation in *T. solium*
- transmission by the animals involved in the program and potentially a 90% reduction in
- transmission within 2 years which could be accelerated by achieving higher coverage in the
- 507 MDA. This reduction would be sustainable through a continuation of the treatments in piglets,
- which could be reduced or terminated after *T. solium* taeniasis levels no longer provided a source
- 509 of new infections. A cost-benefit analysis of this program is currently underway to provide the
- 510 further evidence needed for validation. In addition, in the case of Madagascar, a map of high-risk
- 511 areas for *T. solium* is being prepared so as to provide decision-makers tools for any further
- 512 implementation of this public good control program.
- 513 In conclusion, this minimum input One Health *T. solium* control program significantly reduced
- 514 parasite transmission. A higher MDA coverage (which is known to be feasible in the program
- area) and 90% piglet coverage would likely deliver a near cessation in transmission, which could
- 516 be sustained by continued piglet treatments. The intervention was delivered as a public health
- 517 program and therefore reflected the real-life challenges when implementing these types of
- 518 programs in the field, providing a possible model for future *T. solium* control programs.

519 Acknowledgement

- 520 We are very grateful to the local authorities at all levels who were involved in the implementation
- and the sensitization of communities program for their invaluable input. The cooperation of all
- 522 inhabitants and pigs farmers in the area who participated in the interventions both in animal and
- 523 human side is very much appreciated. And the program couldn't have been implemented without
- the hard work and support from all the health agents, community health agents, and medical staff
- supporting the MDA, as well as all the pig vaccinators, and veterinarians involved in the pig
- activities. The success of the program is a credit to them. Support is acknowledge from the
- 527 Ministry of Health, the Ministry of Agriculture and Livestock and the Ministry of Scientific
- 528 Research and Higher Education.
- 529

530 **References**

- 531
- Garcia HH, Gonzalez AE, Gilman RH. *Taenia solium* cysticercosis and its impact in neurological disease. Clin Microbiol Rev. 2020;33(3). Epub 2020/05/29. doi: 10.1128/CMR.00085-19. PubMed PMID: 32461308; PubMed Central PMCID: PMCPMC7254859.
- Donadeu M, Lightowlers MW, Fahrion AS, Kessels J, Abela-Ridder B. *Taenia solium*:
 WHO endemicity map update. Wkly Epidemiol Rec. 2016;91(49-50):595-9. PubMed PMID:
 27966846.

- Carod JF, Mauny F, Parmentier AL, Desmarets M, Rakotondrazaka M, Brembilla A, et al. Hyperendemicity of cysticercosis in Madagascar: Novel insights from school children population-based antigen prevalence study. PLoS One. 2021;16(10):e0258035. Epub 2021/10/02. doi: 10.1371/journal.pone.0258035. PubMed PMID: 34597322; PubMed Central PMCID: PMCPMC8486106.
- Ndimubanzi PC, Carabin H, Budke CM, Nguyen H, Qian YJ, Rainwater E, et al. A
 systematic review of the frequency of neurocyticercosis with a focus on people with
 epilepsy. PLoS Negl Trop Dis. 2010;4(11):e870. doi: 10.1371/journal.pntd.0000870.
 PubMed PMID: 21072231; PubMed Central PMCID: PMC2970544.
- 5. Anonymus. Update: International Task Force for Disease Eradication. Morbitidy and
 Mortality Weekly Report. 1992;41(691):697-8.
- 6. Cruz M, Davis A, Dixon H, Pawlowski ZS, Proano J. Operational studies on the control of *Taenia solium* taeniasis/cysticercosis in Ecuador. Bull World Health Organ. 1989;67(4):4017. Epub 1989/01/01. PubMed PMID: 2805217; PubMed Central PMCID: PMCPMC2491261.
- Sarti E, Schantz PM, Avila G, Ambrosio J, Medina-Santillan R, Flisser A. Mass treatment against human taeniasis for the control of cysticercosis: a population-based intervention study. Trans R Soc Trop Med Hyg. 2000;94(1):85-9. Epub 2000/04/05. PubMed PMID: 10748908.
- Allan JC, Velasquez-Tohom M, Fletes C, Torres-Alvarez R, Lopez-Virula G, Yurrita P, et al.
 Mass chemotherapy for intestinal *Taenia solium* infection: effect on prevalence in humans and pigs. Trans R Soc Trop Med Hyg. 1997;91(5):595-8. Epub 1998/02/17. PubMed PMID: 9463679.
- 9. Ramiandrasoa NS, Ravoniarimbinina P, Solofoniaina AR, Andrianjafy Rakotomanga IP,
 Andrianarisoa SH, Molia S, et al. Impact of a 3-year mass drug administration pilot project
 for taeniasis control in Madagascar. PLoS Negl Trop Dis. 2020;14(9):e0008653. Epub
 2020/09/19. doi: 10.1371/journal.pntd.0008653. PubMed PMID: 32946447; PubMed Central
 PMCID: PMCPMC7500903.
- Poudel I, Sah K, Subedi S, Kumar Singh D, Kushwaha P, Colston A, et al. Implementation of a practical and effective pilot intervention against transmission of *Taenia solium* by pigs in the Banke district of Nepal. PLoS Negl Trop Dis. 2019;13(2):e0006838. Epub 2019/02/26. doi: 10.1371/journal.pntd.0006838. PubMed PMID: 30802248; PubMed Central PMCID: PMCPMC6405169.
- Assana E, Kyngdon CT, Gauci CG, Geerts S, Dorny P, De Deken R, et al. Elimination of *Taenia solium* transmission to pigs in a field trial of the TSOL18 vaccine in Cameroon. Int J
 Parasitol. 2010;40(5):515-9. doi: 10.1016/j.ijpara.2010.01.006. PubMed PMID: 20138046;
 PubMed Central PMCID: PMC2856920.
- 12. Nsadha Z, Rutebarika C, Ayebazibwe C, Aloys B, Mwanja M, Poole EJ, et al. Control trial
 of porcine cysticercosis in Uganda using a combination of the TSOL18 vaccination and
 oxfendazole. Infect Dis Poverty. 2021;10(1):34. Epub 2021/03/22. doi: 10.1186/s40249-02100823-6. PubMed PMID: 33743828; PubMed Central PMCID: PMCPMC7981864.

- 13. Garcia HH, Gonzalez AE, Tsang VC, O'Neal SE, Llanos-Zavalaga F, Gonzalvez G, et al.
 Elimination of *Taenia solium* transmission in northern Peru. N Engl J Med.
 2016;374(24):2335-44. doi: 10.1056/NEJMoa1515520. PubMed PMID: 27305193; PubMed
 Central PMCID: PMCPMC4962610.
- 14. Gabriel S, Mwape KE, Hobbs EC, Devleesschauwer B, Van Damme I, Zulu G, et al.
 Evidence for potential elimination of active *Taenia solium* transmission in Africa? N Engl J
 Med. 2020;383(4):396-7. Epub 2020/07/24. doi: 10.1056/NEJMc1909955. PubMed PMID:
 32699455; PubMed Central PMCID: PMCPMC7289521.
- 588 15. O'Neal SE, Moyano LM, Ayvar V, Rodriguez S, Gavidia C, Wilkins PP, et al. Ringscreening to control endemic transmission of *Taenia solium*. PLoS Negl Trop Dis.
 2014;8(9):e3125. Epub 2014/09/12. doi: 10.1371/journal.pntd.0003125. PubMed PMID:
 25210748; PubMed Central PMCID: PMCPMC4161340.
- Beam M, Spencer A, Fernandez L, Atto R, Muro C, Vilchez P, et al. Barriers to participation
 in a community-based program to control transmission of *Taenia solium* in Peru. Am J Trop
 Med Hyg. 2018. Epub 2018/04/18. doi: 10.4269/ajtmh.17-0929. PubMed PMID: 29663901.
- 595 17. O'Neal SE, Pray IW, Vilchez P, Gamboa R, Muro C, Moyano LM, et al. Geographically
 596 targeted interventions versus mass drug administration to control *Taenia solium*597 cysticercosis, Peru. Emerging infectious diseases. 2021;27(9):2389-98. doi:
 598 10.3201/eid2709.203349.
- 18. INSTAT. Troisième Recensement Général de la Population et de l'Habitation (RGPH-3).
 Résultats Globaux du Recensement Général de la Population et de l'Habitation de 2018 de Madagascar (RGPH-3). Tome 1 and 2, 2020.
- Rakotoarisoa J, Bélières J-F, Salgado P. Agricultural intensification in Madagascar: public
 policies and pathways of farms in the Vakinankaratra region. PROIntens Africa Initiative
 [Internet]. 2016. Available from: https://agritrop.cirad.fr/582242/.
- 20. Zafindraibe NJ, Ralalarinivo J, Rakotoniaina AI, Maeder MN, Andrianarivelo MR,
 Contamin B, et al. [Seroprevalence of cysticercosis and associated risk factors in a group of
 patients examined at the Regional Referral Hospital in Antsirabe]. Pan Afr Med J.
 2017;28:260. Epub 2018/06/09. doi: 10.11604/pamj.2017.28.260.10463. PubMed PMID:
 29881503; PubMed Central PMCID: PMCPMC5989193.
- Sourisseau J-M, Rasolofo P, Bélières J-F, Guengant J-P, Ramanitriniony HK, Bourgeois R,
 et al. Diagnostic territorial de la région du Vakinankaratra à Madagascar 2016. Available
 from: https://agritrop.cirad.fr/580518/.
- 22. Rasamoelina-Andriamanivo H, Porphyre V, Jambou R. Control of cysticercosis in
 Madagascar: beware of the pitfalls. Trends Parasitol. 2013;29(11):538-47. Epub 2013/10/23.
 doi: 10.1016/j.pt.2013.09.002. PubMed PMID: 24145061.
- Lightowlers MW, Donadeu M, Elaiyaraja M, Maithal K, Kumar KA, Gauci CG, et al.
 Anamnestic responses in pigs to the *Taenia solium* TSOL18 vaccine and implications for
 control strategies. Parasitology. 2016;143(4):416-20. doi: 10.1017/S0031182016000202.
 PubMed PMID: 26892239.

World Health Organization, World Organisation for Animal Health, Food and Agriculture
Organization of the United Nations (FAO). How to prevent the pork tapeworm? A neglected
parasitic infection caused by *Taenia solium* - Poster. 2022.

- Mananjara DEA, Rakotoarinoro M, Rakotoarison VC, Raliniaina M, Razafindraibe NP,
 Ravonirina C, et al. Confirmation by necropsy of a high prevalence of porcine cysticercosis
 in a rural district of Madagascar. Parasitology. 2023;150(9):852-7. Epub 2023/07/27. doi:
 10.1017/S0031182023000653. PubMed PMID: 37496390; PubMed Central PMCID:
 PMCPMC10478050.
- 628 26. World Health Organization. Bench Aid for the diagnosis of intestinal parasites Second
 629 edition. Geneve: World Health Organization; 2019.
- 27. Lightowlers MW, Mananjara DEA, Rakotoarinoro M, Rakotoarison VC, Raliniaina M,
 Rasamoelina-Andriamanivo H, et al. Comparison of Kato-Katz, PCR and coproantigen for
 the diagnosis of *Taenia solium* taeniasis. Parasitology. 2023:1-7. Epub 2023/08/25. doi:
 10.1017/S0031182023000690. PubMed PMID: 37621007.
- 634 28. Gauci CG, Ito A, Lightowlers MW. Conservation of the vaccine antigen gene, TSOL18,
 635 among genetically variant isolates of *Taenia solium*. Mol Biochem Parasitol.
 636 2006;146(1):101-4. doi: 10.1016/j.molbiopara.2005.10.014. PubMed PMID: 16298439.
- 637 29. Gonzalez AE, Falcon N, Gavidia C, Garcia HH, Tsang VC, Bernal T, et al. Time-response
 638 curve of oxfendazole in the treatment of swine cysticercosis. Am J Trop Med Hyg.
 639 1998;59(5):832-6. PubMed PMID: 9840607.
- 30. Sikasunge CS, Johansen MV, Willingham AL, 3rd, Leifsson PS, Phiri IK. *Taenia solium*porcine cysticercosis: viability of cysticerci and persistency of antibodies and cysticercal
 antigens after treatment with oxfendazole. Vet Parasitol. 2008;158(1-2):57-66. doi:
 10.1016/j.vetpar.2008.08.014. PubMed PMID: 18834668.
- Alvarez L, Saumell C, Fuse L, Moreno L, Ceballos L, Domingue G, et al. Efficacy of a
 single high oxfendazole dose against gastrointestinal nematodes in naturally infected pigs.
 Vet Parasitol. 2013;194(1):70-4. doi: 10.1016/j.vetpar.2013.01.003. PubMed PMID:
 23357598.
- 648 32. Ortiz P, Terrones S, Cabrera M, Hoban C, Ceballos L, Moreno L, et al. Oxfendazole
 649 flukicidal activity in pigs. Acta Trop. 2014;136:10-3. doi: 10.1016/j.actatropica.2014.03.024.
 650 PubMed PMID: 24713198.
- 33. World Health Organization. Symptoms and signs compatible with neurocysticercosis in relation to preventive chemotherapy 2023:[3 p.]. Available from:
 https://www.who.int/publications/i/item/9789240068117.
- World Health Organization. Early detection and management of neurological serious adverse
 events in relation to the administration of anthelminthic medicines to people with
- asymptomatic neurocysticercosis2023:[8 p.]. Available from:
- 657 https://www.who.int/publications/i/item/9789240068131.